Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2021 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
October 07, 2021 16:15 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial

Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to TherapyInvestigation...
September 20, 2021 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
September 01, 2021 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
August 12, 2021 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma PatientsPhase 1 Data from the ALLO-715 UNIVERSAL Trial Demonstrated for the First Time...
August 04, 2021 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Second Quarter 2021 Financial Results

CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable Response Rates on Par with Autologous CD19...
August 02, 2021 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
July 27, 2021 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
July 12, 2021 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
June 30, 2021 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 IGNITE Dose Escalation Trial of ALLO-605 Initiated in Q2 2021ALLO-605 is the Third Prong of the Company’s Clinical Strategy to Target BCMA for the Treatment of Multiple MyelomaTurboCARTM...